A Center Based Early Intervention Program For Preschoolers With Developmental Disorders

Sponsor
Stanford University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04026386
Collaborator
John & Marcia Goldman Foundation (Other)
75
1
1
61.4
1.2

Study Details

Study Description

Brief Summary

The purpose of this study is to examine the effectiveness of a 12-week early intervention program that will include 12 weekly hours in an intensive center-based preschool environment to treat social communication deficits in children with developmental disorders. The study will include children with developmental disorders, such as Autism Spectrum Disorder, neurogenetic disorders, or intellectual disability.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Center Based Early Intervention Program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Center Based Early Intervention Program For Preschoolers With Developmental Disorders
Actual Study Start Date :
Oct 19, 2019
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Center Based Early Intervention Program

Behavioral: Center Based Early Intervention Program
This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment to treat social communication deficits in children with developmental disorders.

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment. [Baseline, 12 Weeks]

    Social Responsiveness Scale, 2nd Edition (SRS) scores measure social abilities with lower scores meaning better social abilities. (T-Score Range: 37- above 90 )

Secondary Outcome Measures

  1. Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment. [Baseline, 12 Weeks]

    Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129)

  2. Change From Baseline in Parent Rated Stanford Social Dimension Scale (SSDS) Scores During Treatment. [Baseline, 12 Weeks]

    Higher Scores on the Stanford Social Dimension Scale mean better social functioning and lower scores mean worse social functioning (Range: 58-290).

  3. Change From Baseline in Parent Rated Vineland Adaptive Behavior Scale- 3 (VABS-3) Scores During Treatment. [Baseline, 12 Weeks]

  4. Change From Baseline in Parent Rated Short Sensory Profile Questionnaire (SSPQ) Scores During Treatment. [Baseline, 12 Weeks]

  5. Change From Baseline in Parent Rated General Self Efficacy Scale (GSES) Scores During Treatment. [Baseline, 12 Weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 4 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Developmental Disorder, such as Autism Spectrum Disorder, neurogenetic disorder, or intellectual disability, based on clinical interview;

  • Boys and girls between 2.0 years and 4.11 years at time of enrollment;

  • Ability to participate in the testing procedures to the extent that valid standard scores can be obtained.

Exclusion Criteria:
  • Current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.);

  • Lack of availability during program hours.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University School of Medicine Stanford California United States 94305

Sponsors and Collaborators

  • Stanford University
  • John & Marcia Goldman Foundation

Investigators

  • Principal Investigator: Antonio Hardan, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonio Hardan, Professor, Stanford University
ClinicalTrials.gov Identifier:
NCT04026386
Other Study ID Numbers:
  • IRB-52348
First Posted:
Jul 19, 2019
Last Update Posted:
Feb 16, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 16, 2022